Kevin Joseph Harrington

52PUBLICATIONS
467CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsChemotherapyTumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (52)

|Jun 26, 2026
Tumour Mutational Burden and Its Relationship with Clinical Outcomes in Locally Advanced and Recurrent/Metastatic Adenoid Cystic Carcinoma with and Without NOTCH Pathway Activation.

|Jun 05, 2026
Engagement of the TCR against an oncolytic virus generates a population of effector CAR T cells with potent antitumor activity.

|May 31, 2026
Amivantamab in Recurrent/Metastatic Head and Neck Squamous Cell Cancer After Checkpoint Inhibitor and Chemotherapy: Pivotal Results From the Phase Ib/II OrigAMI-4 Study.

|Mar 31, 2026
Phase 1 study of ceralasertib, an ATR kinase inhibitor, in combination with durvalumab in patients with recurrent or metastatic NSCLC or HNSCC.

Juanita S Lopez, Kevin J Harrington, Seock-Ah Im

|Mar 12, 2026
Pembrolizumab With or Without Lenvatinib as First-Line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Phase III LEAP-010 Study.

Lisa Licitra, Makoto Tahara, Kevin Harrington

|Mar 03, 2026
Effects of oncolytic immunotherapy with RP1 (vusolimogene oderparepvec) on immune cells mediate responsiveness to anti-PD-1 via STING-mediated interferon signaling.

Victoria Roulstone, Joan Kyula, Elizabeth Appleton

Pageof 9

Frequent Collaborators

15 joint publications

Alan Melcher

11 joint publications

Emmanuel Patin

8 joint publications

Pablo Nenclares

8 joint publications

Robert I Haddad